Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): Results from OVA-301 follow-up.

Nicoletta Colombo,Antonio Casado,Consuelo Fernández,Ignace Vergote

Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): Results from OVA-301 follow-up.

2014

Nicoletta Colombo
Antonio Casado
Consuelo Fernández
Ignace Vergote

5551 Background: OVA-301, a randomized phase III study of trabectedin plus PLD (n=337) vs. PLD alone (n=335) in patients with ROC demonstrated a statistically longer progression-free survival (PFS)...

Keywords:

Pegylated Liposomal Doxorubicin
Oncology
Pathology
Trabectedin
Platinum
Recurrent Ovarian Cancer
Internal medicine
Chemotherapy
Medicine
platinum resistant
platinum chemotherapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations